NEW YORK (GenomeWeb News) – Geisinger Health System today announced a partnership with German firm Indivumed aimed at providing Geisinger's patients access to advanced cancer treatments and clinical trials.

Under the terms of the deal, Indivumed will have access to tissue samples from consenting Geisinger patients for molecular and biochemical profiling. Patients already undergoing a surgical tumor resection will have a portion of the tissue, blood, or urine banked by Geisinger through MyCode, a repository that currently contains 43,000 patient samples.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.